Canadian Paediatric Surveillance Program: A developmental check-up

Abstract

Just as children are born, grow and develop, so too do programs. In 1996, as a medical officer of health, I attended the first steering committee meeting in Ottawa to witness the birth of the Canadian Paediatric Surveillance Program (CPSP), a new overseas cousin to the now 10-year-old British program. Little did I, and others at the meeting, realize how much time and attention this new baby would require. The CPSP, like any developing infant, required nurturing. As it grew, the number of surveillance activities increased. It started slowly with the reporting of three paediatric infectious diseases with important public health implications: acute flaccid paralysis as part of polio surveillance, congenital rubella syndrome and neonatal group B streptococcal infection. As the CPSP gained experience, it extended its reach to undertake surveillance of up to 10 conditions simultaneously. It has now been involved with a total of 24 important paediatric conditions covering areas such as infectious diseases, injuries, genetic disorders, metabolic conditions and neurological problems (Table 1). At first, the CPSP had to actively seek out conditions for surveillance, but as its reputation grew, an increasing number of investigators came forward with proposed studies. At the last steering committee meeting, a list of 30 proposed new CPSP studies was presented to the group. As the program approached seven years of age, Health Canada and the Canadian Paediatric Society decided that a developmental check-up was needed to see if the CPSP was maturing according to expectations. Assessing the CPSP’s adaptability to respond effectively to the changing Canadian health care delivery environment was also deemed essential. An internal CPSP evaluation team was created to supervise the evaluation, and a public health epidemiologist was contracted to assist in the process. An external international advisory group was formed with expertise in paediatrics, surveillance, public health and policy development to provide input into the objectives and methodology of the evaluation. A review of the literature indicated that only one other national paediatric surveillance unit, the Australian Paediatric Surveillance Unit, had undergone a formal evaluation, based primarily on the criteria used by the Centers for Disease Control and Prevention for evaluation of a surveillance program (1,2). This, together with other literature on the evaluation of public health programs, served as references to develop and implement an evaluation process (3). Evaluation objectives were created with the emphasis placed on ensuring feedback from program participants who were frontline paediatricians, researchers and public health policy makers. Survey questions were sent to over 2469 participants. The survey included specific questions, but also allowed respondents the opportunity to provide suggestions on how the program could be improved. In addition, a review of the health conditions that had undergone surveillance was performed to see how accurately the program was able to detect the true number of events. The expert advisory group met with the evaluation team for a full day to receive and review the results of the evaluation. The advisory group then caucused separately to review their analysis and provide both immediate verbal and later written comment on the CPSP. While the results of the evaluation, the recommendations from the expert group and the proposed changes to the CPSP will be provided to readers in the months ahead through posters, articles and published manuscripts, some key points are worth noting. It is clear that the CPSP has developed into an effective infrastructure for national collaborative surveillance and research into paediatric conditions. These conditions, although occurring at a low frequency, may have a high impact on society in terms of morbidity, mortality and cost. It is an excellent value for the money and it is unique in Canada as an ongoing collaborative tool for surveillance and research that provides supporting evidence for policy development. The reach of the program extends beyond Canada as the program continues to provide surveillance results and to collaborate on common surveillance activities with 13 other members of INoPSU (International Network of Paediatric Surveillance Units) (4). Most importantly, the CPSP, through its surveillance activities, provides evidence that can be used to guide actions to improve children’s health, such as improved clinical recognition and management or beneficial changes in policy development. Several examples include the work on vitamin D deficiency rickets, hemorrhagic disease of the newborn due to problems with vitamin K administration, and injuries due to baby walkers. EDITORIAL